NCT05987176 - Comparison of Adjuvant Treatment With 177Lu-DOTATATE to Best Supportive Care in Patients After Resection of Neuroendocrine Liver Metastases | Biotech Hunter

Enrollment

106

Participants

Timeline

Start Date

August 2, 2024

Primary Completion Date

September 1, 2028

Study Completion Date

March 30, 2029

Conditions

Neuroendocrine Tumor G1 (NET G1)/CarcinoidNeuroendocrine Tumor Grade 2Neuroendocrine TumorsLiver MetastasesGastroenteropancreatic Neuroendocrine TumorGastroenteropancreatic Neuroendocrine Neoplasm

Interventions

DRUG

Lutathera

"Dosage:~In total 14.8 GBq (400 mCi) 177Lu-DOTATATE administered in two equally divided doses. Each dose to be infused over 30 minutes.~Duration of treatment:~Two administrations of 177Lu-DOTATATE (each treatment 7.4 GBQ (200 mCi) at 8±1-week intervals, which can be extended to 16 weeks for resolving acute toxicity."

Trial Locations (1)

W12 0HS

RECRUITING

Imperial College Healthcare NHS Trust, London